Mirati Therapeutics Announces Departure Of Chief Executive Officer David Meek; Charles M. Baum, M.D., Ph.D. Assumes Role Of Interim CEO
Charles M. Baum, M.D., Ph.D. assumes role of interim CEO
SAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company today announced